Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tg Therapeutics (NQ: TGTX )

34.55 +3.40 (+10.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tg Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021
Upgrades For Targa Resources Corp (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers EyePoint Pharmaceuticals (NASDAQ:EYPT) stock increased by 44.96% to $20.31 during Monday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
TG Therapeutics, inc (TGTX) Q3 2021 Earnings Call Transcript
TGTX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Emotions Wreak Havoc On Healthcare Investments
If you buy shares of a stock like Target, of course you want the company to prosper. But let’s face it, you probably don’t get that excited about the same-store sales report each month. But when you... 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Regencell Bioscience (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest... 
Via Benzinga
Exposures COVID-19 Product Safety
Understanding TG Therapeutics's Unusual Options Activity
TG Therapeutics (NASDAQ:TGTX) shares experienced unusual options activity on Monday. The stock price moved down to $22.62 following the option alert. Sentiment: BEARISH Option... 
Via Benzinga
Looking into TG Therapeutics's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, TG Therapeutics (NASDAQ:TGTX) posted sales of $1.54 million. Earnings were up 13.36%, but TG Therapeutics still... 
Via Benzinga
TG Therapeutics, inc (TGTX) Q2 2021 Earnings Call Transcript
TGTX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why TG Therapeutics Shares Are Trading Lower Today
TG Therapeutics Inc (NASDAQ: TGTX) is trading lower Monday after the company announced worse-than-expected second-quarter financial results and H.C. Wainwright lowered its... 
Via Benzinga
TG Therapeutics Stock Plunged As H.C. Wainwright Cuts Target Price After Disappointing Q2
H.C. Wainwright has lowered TG Therapeutics Inc's (NASDAQ: 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Gains 50 Points; Marin Software Shares Plummet
Toward the end of trading Monday, the Dow traded up 0.02% to 34,941.69 while the NASDAQ rose 0.37% to 14,727.42. The S&P also rose, gaining 0.10% to 4,399.45. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
61 Biggest Movers From Yesterday
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.... 
Via Benzinga
Here's Why TG Therapeutics Stock Is Getting Hammered Today
A second-quarter earnings report reminded investors how difficult it is for independent companies to launch new cancer drugs. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock increased by 35.01% to $5.5 during Monday's regular session. Trading volume for Xenetic Biosciences's stock is 10.1... 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 2.5%; Exicure Shares Spike Higher
Midway through trading Monday, the Dow traded up 0.35% to 35,058.26 while the NASDAQ rose 0.52% to 14,748.83. The S&P also rose, gaining 0.39% to 4,412.29. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
40 Stocks Moving In Monday's Mid-Day Session
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Global Payments Posts Upbeat Q2 Earnings
Following the market opening Monday, the Dow traded up 0.58% to 35,138.90 while the NASDAQ rose 0.40% to 14,731.03. The S&P also rose, gaining 0.46% to 4,415.36. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Brickell Biotech (NASDAQ:BBI) stoc... 
Via Benzinga
Looking Into TG Therapeutics's Return On Capital Employed
During Q1, TG Therapeutics's (NASDAQ:TGTX) reported sales totaled $793.00 thousand. Despite a 2.07% in earnings, the company posted a loss of $88.73 million. In Q4, TG... 
Via Benzinga
Return On Capital Employed Overview: TG Therapeutics
In Q1, TG Therapeutics (NASDAQ:TGTX) posted sales of $793.00 thousand. Earnings were up 2.07%, but TG Therapeutics still reported an overall loss of $88.73 million. In Q4, TG... 
Via Benzinga
TG Therapeutics' Ublituximab-Umbralisib Combo Application Under FDA Review for Hematological Malignancies
The FDA has accepted for review TG Therapeutics Inc's (NASDAQ: TGTX) marketing application seeking approval for ublituximab in combination with Ukoniq (... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For August 2, 2021
Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is estimated to report earnings for its second quarter. • Addex Therapeutics (NASDAQ:ADXN) is... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
TG Therapeutics Inc (TGTX) Q1 2021 Earnings Call Transcript
TGTX earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: TG Therapeutics Q1 Earnings
Shares of TG Therapeutics (NASDAQ:TGTX) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were down 43.75% year over year to... 
Via Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.